Angela is passionate about creating new technology platforms for translational research that will close the gap between life science, engineering, and the clinic. In 2015, Angela also co-founded Agenovir, a genome-editing based anti-viral therapeutics start-up company currently based in South San Francisco. During Angela's time at Agenovir, in addition to managing R and D, she worked directly with the CEO on business development strategies and fund-raising to successfully raise Series A financing. Recently, Angela was named one of ten MIT Technology Review's Innovators under 35 in Asia.